The Relevance of Using the C3d/IgG Test in Clinical Intervention

Background: A large subset of the population is afflicted with a wide range of foodrelated inflammatory conditions, with at least 100 million people affected worldwide. Primary Study Objective: To validate the food sensitivity C3d/IgG test for its ability to manage patients with intestinal and extraintestinal symptoms. Methods: The study was a retrospective analysis of 30 subjects ranging from age 7-71, consisting of 9 males and 21 females. Outcomes are based upon the status of primary complaints after being placed on an exclusion dietary regimen based on elevated serum C3d/IgG food-specific antibodies. Two C3d/IgG tests were performed on the patient’s serum by the method of Indirect Enzyme Linked Immunosorbent Assay (ELISA). From the initial test, elevated anti C3d/IgG foods were identified and eliminated from patient’s diet. Subjects were retested at an average of 10.7 months; both food sensitivities and chief complaints were reassessed. Intervention: The C3d/IgG test measures both the innate and adaptive responses of the immune system. The test quantifies IgG antibodies and the inflammatory biomarker, C3d, with magnitude of reaction on a scale of severe, high, moderate and mild. Food reactions with the exception of mild were eliminated from the individual’s diet. Then subjects were retested to determine if their symptoms improve with food elimination. Results: Patients who complied with the avoidance of anti-C3d/IgG dietary antigens demonstrated statistically significant reduction in C3d/IgG testing sensitivity, and marked reduction in symptoms that they reported before beginning the diet. The p-values are 1.56E-06, 0.007, and 0.001 for the severe, high, and moderate test results between the initial and second test. Conclusion: Overall, patient well-being improved when C3d/IgG food sensitivity decreased as a result of an exclusion diet, demonstrating food removal based on the C3d/IgG test is an effective approach in patient care.